We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
KemPharm announced the United States Patent and Trademark Office (USPTO) has recently issued two new patents to KemPharm governing methods of use and composition of matter for methylphenidate-based prodrugs.
KemPharm has submitted a New Drug Application (NDA) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for its investigational product candidate, KP415, to the U.S. Food and Drug Administration (FDA).